Advertisement

Index by author

October 01, 1995; Volume 23,Issue 10

B

  1. Benet, L Z

    1. Stereoselective disposition of naproxen glucuronide in the rat.
      M Iwaki, A Bischer, A C Nguyen, A F McDonagh and L Z Benet
      Drug Metabolism and Disposition October 1995, 23 (10) 1099-1103;

  2. Bergeron, R J

    1. Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.
      R J Bergeron, W R Weimar, G Luchetta, R R Streiff, J Wiegand, J Perrin, K M Schreier, C Porter, G W Yao and H Dimova
      Drug Metabolism and Disposition October 1995, 23 (10) 1117-1125;

  3. Bhargava, R

    1. Liver volume as a determinant of drug clearance in children and adolescents.
      D J Murry, W R Crom, W E Reddick, R Bhargava and W E Evans
      Drug Metabolism and Disposition October 1995, 23 (10) 1110-1116;

  4. Bischer, A

    1. Stereoselective disposition of naproxen glucuronide in the rat.
      M Iwaki, A Bischer, A C Nguyen, A F McDonagh and L Z Benet
      Drug Metabolism and Disposition October 1995, 23 (10) 1099-1103;

  5. Bugelski, P J

    1. Renal catabolism of recombinant human soluble CD4 after intravenous administration to male Sprague-Dawley rats.
      T W Hepburn, C B Davis, J J Urbanski, B R Smith, W H Schaefer, M A Carbonaro and P J Bugelski
      Drug Metabolism and Disposition October 1995, 23 (10) 1044-1050;

C

  1. Carbonaro, M A

    1. Renal catabolism of recombinant human soluble CD4 after intravenous administration to male Sprague-Dawley rats.
      T W Hepburn, C B Davis, J J Urbanski, B R Smith, W H Schaefer, M A Carbonaro and P J Bugelski
      Drug Metabolism and Disposition October 1995, 23 (10) 1044-1050;

  2. Cashman, J R

    1. In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N'-oxidation.
      A D Rodrigues, M J Kukulka, J L Ferrero and J R Cashman
      Drug Metabolism and Disposition October 1995, 23 (10) 1143-1152;

  3. Castle, P J

    1. Human liver lauric acid hydroxylase activities.
      P J Castle, J L Merdink, J R Okita, S A Wrighton and R T Okita
      Drug Metabolism and Disposition October 1995, 23 (10) 1037-1043;

  4. Chiu, S H

    1. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.
      S W Huskey, D C Dean, R R Miller, G H Rasmusson and S H Chiu
      Drug Metabolism and Disposition October 1995, 23 (10) 1126-1135;

  5. Coassolo, P

    1. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
      B Valles, C D Schiller, P Coassolo, G De Sousa, R Wyss, D Jaeck, A Viger-Chougnet and R Rahmani
      Drug Metabolism and Disposition October 1995, 23 (10) 1051-1057;

  6. Crom, W R

    1. Liver volume as a determinant of drug clearance in children and adolescents.
      D J Murry, W R Crom, W E Reddick, R Bhargava and W E Evans
      Drug Metabolism and Disposition October 1995, 23 (10) 1110-1116;

  7. Crooks, P A

    1. Determination of nicotine metabolites in rat brain after peripheral radiolabeled nicotine administration: detection of nornicotine.
      P A Crooks, M Li and L P Dwoskin
      Drug Metabolism and Disposition October 1995, 23 (10) 1175-1177;

D

  1. Davies, M I

    1. Microdialysis sampling for hepatic metabolism studies. Impact of microdialysis probe design and implantation technique on liver tissue.
      M I Davies and C E Lunte
      Drug Metabolism and Disposition October 1995, 23 (10) 1072-1079;

  2. Davis, C B

    1. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.
      C B Davis, T W Hepburn, J J Urbanski, D C Kwok, T K Hart, D J Herzyk, S G Demuth, M Leland and G R Rhodes
      Drug Metabolism and Disposition October 1995, 23 (10) 1028-1036;
    2. Renal catabolism of recombinant human soluble CD4 after intravenous administration to male Sprague-Dawley rats.
      T W Hepburn, C B Davis, J J Urbanski, B R Smith, W H Schaefer, M A Carbonaro and P J Bugelski
      Drug Metabolism and Disposition October 1995, 23 (10) 1044-1050;

  3. Dean, D C

    1. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.
      S W Huskey, D C Dean, R R Miller, G H Rasmusson and S H Chiu
      Drug Metabolism and Disposition October 1995, 23 (10) 1126-1135;

  4. Demuth, S G

    1. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.
      C B Davis, T W Hepburn, J J Urbanski, D C Kwok, T K Hart, D J Herzyk, S G Demuth, M Leland and G R Rhodes
      Drug Metabolism and Disposition October 1995, 23 (10) 1028-1036;

  5. De Sousa, G

    1. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
      B Valles, C D Schiller, P Coassolo, G De Sousa, R Wyss, D Jaeck, A Viger-Chougnet and R Rahmani
      Drug Metabolism and Disposition October 1995, 23 (10) 1051-1057;

  6. Dimova, H

    1. Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.
      R J Bergeron, W R Weimar, G Luchetta, R R Streiff, J Wiegand, J Perrin, K M Schreier, C Porter, G W Yao and H Dimova
      Drug Metabolism and Disposition October 1995, 23 (10) 1117-1125;

  7. Dwoskin, L P

    1. Determination of nicotine metabolites in rat brain after peripheral radiolabeled nicotine administration: detection of nornicotine.
      P A Crooks, M Li and L P Dwoskin
      Drug Metabolism and Disposition October 1995, 23 (10) 1175-1177;

E

  1. Endo, T

    1. Interindividual variation in carboxylesterase levels in human liver microsomes.
      M Hosokawa, T Endo, M Fujisawa, S Hara, N Iwata, Y Sato and T Satoh
      Drug Metabolism and Disposition October 1995, 23 (10) 1022-1027;

  2. Evans, W E

    1. Liver volume as a determinant of drug clearance in children and adolescents.
      D J Murry, W R Crom, W E Reddick, R Bhargava and W E Evans
      Drug Metabolism and Disposition October 1995, 23 (10) 1110-1116;

F

  1. Faiman, M D

    1. Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N,N-diethylthiolcarbamate (DETC-ME). The terminal step in the bioactivation of disulfiram.
      A Madan, A Parkinson and M D Faiman
      Drug Metabolism and Disposition October 1995, 23 (10) 1153-1162;

  2. Ferrero, J L

    1. In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N'-oxidation.
      A D Rodrigues, M J Kukulka, J L Ferrero and J R Cashman
      Drug Metabolism and Disposition October 1995, 23 (10) 1143-1152;
    2. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.
      J M Machinist, M D Mayer, M S Shet, J L Ferrero and A D Rodrigues
      Drug Metabolism and Disposition October 1995, 23 (10) 1163-1174;

  3. Fredenburg, A M

    1. Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators.
      R A Yokel, A M Fredenburg, K A Meurer and T L Skinner
      Drug Metabolism and Disposition October 1995, 23 (10) 1178-1180;

  4. Fujisawa, M

    1. Interindividual variation in carboxylesterase levels in human liver microsomes.
      M Hosokawa, T Endo, M Fujisawa, S Hara, N Iwata, Y Sato and T Satoh
      Drug Metabolism and Disposition October 1995, 23 (10) 1022-1027;

G

  1. Gupta, N

    1. Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile.
      D A Nicoll-Griffith, N Gupta, S P Twa, H Williams, L A Trimble and J A Yergey
      Drug Metabolism and Disposition October 1995, 23 (10) 1085-1093;

H

  1. Hara, S

    1. Interindividual variation in carboxylesterase levels in human liver microsomes.
      M Hosokawa, T Endo, M Fujisawa, S Hara, N Iwata, Y Sato and T Satoh
      Drug Metabolism and Disposition October 1995, 23 (10) 1022-1027;

  2. Hart, T K

    1. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.
      C B Davis, T W Hepburn, J J Urbanski, D C Kwok, T K Hart, D J Herzyk, S G Demuth, M Leland and G R Rhodes
      Drug Metabolism and Disposition October 1995, 23 (10) 1028-1036;

  3. Hepburn, T W

    1. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.
      C B Davis, T W Hepburn, J J Urbanski, D C Kwok, T K Hart, D J Herzyk, S G Demuth, M Leland and G R Rhodes
      Drug Metabolism and Disposition October 1995, 23 (10) 1028-1036;
    2. Renal catabolism of recombinant human soluble CD4 after intravenous administration to male Sprague-Dawley rats.
      T W Hepburn, C B Davis, J J Urbanski, B R Smith, W H Schaefer, M A Carbonaro and P J Bugelski
      Drug Metabolism and Disposition October 1995, 23 (10) 1044-1050;

  4. Herzyk, D J

    1. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.
      C B Davis, T W Hepburn, J J Urbanski, D C Kwok, T K Hart, D J Herzyk, S G Demuth, M Leland and G R Rhodes
      Drug Metabolism and Disposition October 1995, 23 (10) 1028-1036;

  5. Hosokawa, M

    1. Interindividual variation in carboxylesterase levels in human liver microsomes.
      M Hosokawa, T Endo, M Fujisawa, S Hara, N Iwata, Y Sato and T Satoh
      Drug Metabolism and Disposition October 1995, 23 (10) 1022-1027;

  6. Huskey, S W

    1. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.
      S W Huskey, D C Dean, R R Miller, G H Rasmusson and S H Chiu
      Drug Metabolism and Disposition October 1995, 23 (10) 1126-1135;

I

  1. Iwaki, M

    1. Stereoselective disposition of naproxen glucuronide in the rat.
      M Iwaki, A Bischer, A C Nguyen, A F McDonagh and L Z Benet
      Drug Metabolism and Disposition October 1995, 23 (10) 1099-1103;

  2. Iwata, N

    1. Interindividual variation in carboxylesterase levels in human liver microsomes.
      M Hosokawa, T Endo, M Fujisawa, S Hara, N Iwata, Y Sato and T Satoh
      Drug Metabolism and Disposition October 1995, 23 (10) 1022-1027;

J

  1. Jaeck, D

    1. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
      B Valles, C D Schiller, P Coassolo, G De Sousa, R Wyss, D Jaeck, A Viger-Chougnet and R Rahmani
      Drug Metabolism and Disposition October 1995, 23 (10) 1051-1057;

  2. Juchau, M R

    1. Xenopus laevis: a model system for the study of embryonic retinoid metabolism. III. Isomerization and metabolism of all-trans-retinoic acid and 9-cis-retinoic acid and their dysmorphogenic effects in embryos during neurulation.
      J C Kraft and M R Juchau
      Drug Metabolism and Disposition October 1995, 23 (10) 1058-1071;

K

  1. Kleiner, H E

    1. Metabolism as a determinant of species susceptibility to 2,3,5-(triglutathion-S-yl)hydroquinone-mediated nephrotoxicity. The role of N-acetylation and N-deacetylation.
      S S Lau, H E Kleiner and T J Monks
      Drug Metabolism and Disposition October 1995, 23 (10) 1136-1142;

  2. Kraft, J C

    1. Xenopus laevis: a model system for the study of embryonic retinoid metabolism. III. Isomerization and metabolism of all-trans-retinoic acid and 9-cis-retinoic acid and their dysmorphogenic effects in embryos during neurulation.
      J C Kraft and M R Juchau
      Drug Metabolism and Disposition October 1995, 23 (10) 1058-1071;

  3. Kukulka, M J

    1. In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N'-oxidation.
      A D Rodrigues, M J Kukulka, J L Ferrero and J R Cashman
      Drug Metabolism and Disposition October 1995, 23 (10) 1143-1152;

  4. Kwok, D C

    1. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.
      C B Davis, T W Hepburn, J J Urbanski, D C Kwok, T K Hart, D J Herzyk, S G Demuth, M Leland and G R Rhodes
      Drug Metabolism and Disposition October 1995, 23 (10) 1028-1036;

L

  1. Lau, S S

    1. Metabolism as a determinant of species susceptibility to 2,3,5-(triglutathion-S-yl)hydroquinone-mediated nephrotoxicity. The role of N-acetylation and N-deacetylation.
      S S Lau, H E Kleiner and T J Monks
      Drug Metabolism and Disposition October 1995, 23 (10) 1136-1142;

  2. Leland, M

    1. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.
      C B Davis, T W Hepburn, J J Urbanski, D C Kwok, T K Hart, D J Herzyk, S G Demuth, M Leland and G R Rhodes
      Drug Metabolism and Disposition October 1995, 23 (10) 1028-1036;

  3. Li, M

    1. Determination of nicotine metabolites in rat brain after peripheral radiolabeled nicotine administration: detection of nornicotine.
      P A Crooks, M Li and L P Dwoskin
      Drug Metabolism and Disposition October 1995, 23 (10) 1175-1177;

  4. Lin, J H

    1. Species similarities and differences in pharmacokinetics.
      J H Lin
      Drug Metabolism and Disposition October 1995, 23 (10) 1008-1021;

  5. Luchetta, G

    1. Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.
      R J Bergeron, W R Weimar, G Luchetta, R R Streiff, J Wiegand, J Perrin, K M Schreier, C Porter, G W Yao and H Dimova
      Drug Metabolism and Disposition October 1995, 23 (10) 1117-1125;

  6. Lunte, C E

    1. Microdialysis sampling for hepatic metabolism studies. Impact of microdialysis probe design and implantation technique on liver tissue.
      M I Davies and C E Lunte
      Drug Metabolism and Disposition October 1995, 23 (10) 1072-1079;

M

  1. Machinist, J M

    1. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.
      J M Machinist, M D Mayer, M S Shet, J L Ferrero and A D Rodrigues
      Drug Metabolism and Disposition October 1995, 23 (10) 1163-1174;

  2. Madan, A

    1. Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N,N-diethylthiolcarbamate (DETC-ME). The terminal step in the bioactivation of disulfiram.
      A Madan, A Parkinson and M D Faiman
      Drug Metabolism and Disposition October 1995, 23 (10) 1153-1162;

  3. Mayer, M D

    1. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.
      J M Machinist, M D Mayer, M S Shet, J L Ferrero and A D Rodrigues
      Drug Metabolism and Disposition October 1995, 23 (10) 1163-1174;

  4. McDonagh, A F

    1. Stereoselective disposition of naproxen glucuronide in the rat.
      M Iwaki, A Bischer, A C Nguyen, A F McDonagh and L Z Benet
      Drug Metabolism and Disposition October 1995, 23 (10) 1099-1103;

  5. Merdink, J L

    1. Human liver lauric acid hydroxylase activities.
      P J Castle, J L Merdink, J R Okita, S A Wrighton and R T Okita
      Drug Metabolism and Disposition October 1995, 23 (10) 1037-1043;

  6. Meurer, K A

    1. Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators.
      R A Yokel, A M Fredenburg, K A Meurer and T L Skinner
      Drug Metabolism and Disposition October 1995, 23 (10) 1178-1180;

  7. Miller, R R

    1. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.
      S W Huskey, D C Dean, R R Miller, G H Rasmusson and S H Chiu
      Drug Metabolism and Disposition October 1995, 23 (10) 1126-1135;

  8. Monks, T J

    1. Metabolism as a determinant of species susceptibility to 2,3,5-(triglutathion-S-yl)hydroquinone-mediated nephrotoxicity. The role of N-acetylation and N-deacetylation.
      S S Lau, H E Kleiner and T J Monks
      Drug Metabolism and Disposition October 1995, 23 (10) 1136-1142;

  9. Murry, D J

    1. Liver volume as a determinant of drug clearance in children and adolescents.
      D J Murry, W R Crom, W E Reddick, R Bhargava and W E Evans
      Drug Metabolism and Disposition October 1995, 23 (10) 1110-1116;

N

  1. Nguyen, A C

    1. Stereoselective disposition of naproxen glucuronide in the rat.
      M Iwaki, A Bischer, A C Nguyen, A F McDonagh and L Z Benet
      Drug Metabolism and Disposition October 1995, 23 (10) 1099-1103;

  2. Nicoll-Griffith, D A

    1. Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile.
      D A Nicoll-Griffith, N Gupta, S P Twa, H Williams, L A Trimble and J A Yergey
      Drug Metabolism and Disposition October 1995, 23 (10) 1085-1093;

O

  1. Okita, J R

    1. Human liver lauric acid hydroxylase activities.
      P J Castle, J L Merdink, J R Okita, S A Wrighton and R T Okita
      Drug Metabolism and Disposition October 1995, 23 (10) 1037-1043;

  2. Okita, R T

    1. Human liver lauric acid hydroxylase activities.
      P J Castle, J L Merdink, J R Okita, S A Wrighton and R T Okita
      Drug Metabolism and Disposition October 1995, 23 (10) 1037-1043;

P

  1. Parkinson, A

    1. Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N,N-diethylthiolcarbamate (DETC-ME). The terminal step in the bioactivation of disulfiram.
      A Madan, A Parkinson and M D Faiman
      Drug Metabolism and Disposition October 1995, 23 (10) 1153-1162;

  2. Perrin, J

    1. Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.
      R J Bergeron, W R Weimar, G Luchetta, R R Streiff, J Wiegand, J Perrin, K M Schreier, C Porter, G W Yao and H Dimova
      Drug Metabolism and Disposition October 1995, 23 (10) 1117-1125;

  3. Porter, C

    1. Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.
      R J Bergeron, W R Weimar, G Luchetta, R R Streiff, J Wiegand, J Perrin, K M Schreier, C Porter, G W Yao and H Dimova
      Drug Metabolism and Disposition October 1995, 23 (10) 1117-1125;

R

  1. Rahmani, R

    1. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
      B Valles, C D Schiller, P Coassolo, G De Sousa, R Wyss, D Jaeck, A Viger-Chougnet and R Rahmani
      Drug Metabolism and Disposition October 1995, 23 (10) 1051-1057;

  2. Rasmusson, G H

    1. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.
      S W Huskey, D C Dean, R R Miller, G H Rasmusson and S H Chiu
      Drug Metabolism and Disposition October 1995, 23 (10) 1126-1135;

  3. Reddick, W E

    1. Liver volume as a determinant of drug clearance in children and adolescents.
      D J Murry, W R Crom, W E Reddick, R Bhargava and W E Evans
      Drug Metabolism and Disposition October 1995, 23 (10) 1110-1116;

  4. Rhodes, G R

    1. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.
      C B Davis, T W Hepburn, J J Urbanski, D C Kwok, T K Hart, D J Herzyk, S G Demuth, M Leland and G R Rhodes
      Drug Metabolism and Disposition October 1995, 23 (10) 1028-1036;

  5. Rodrigues, A D

    1. In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N'-oxidation.
      A D Rodrigues, M J Kukulka, J L Ferrero and J R Cashman
      Drug Metabolism and Disposition October 1995, 23 (10) 1143-1152;
    2. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.
      J M Machinist, M D Mayer, M S Shet, J L Ferrero and A D Rodrigues
      Drug Metabolism and Disposition October 1995, 23 (10) 1163-1174;

S

  1. Sanders, R A

    1. Minimal effects of two aldose reductase inhibitors, AL-1576 and AL-4114, after subacute topical-ocular dosing on xenobiotic biotransformation in rabbits.
      S G Sastry, R A Sanders, J C Veltman and J B Watkins
      Drug Metabolism and Disposition October 1995, 23 (10) 1094-1098;

  2. Sastry, S G

    1. Minimal effects of two aldose reductase inhibitors, AL-1576 and AL-4114, after subacute topical-ocular dosing on xenobiotic biotransformation in rabbits.
      S G Sastry, R A Sanders, J C Veltman and J B Watkins
      Drug Metabolism and Disposition October 1995, 23 (10) 1094-1098;

  3. Sato, Y

    1. Interindividual variation in carboxylesterase levels in human liver microsomes.
      M Hosokawa, T Endo, M Fujisawa, S Hara, N Iwata, Y Sato and T Satoh
      Drug Metabolism and Disposition October 1995, 23 (10) 1022-1027;

  4. Satoh, T

    1. Interindividual variation in carboxylesterase levels in human liver microsomes.
      M Hosokawa, T Endo, M Fujisawa, S Hara, N Iwata, Y Sato and T Satoh
      Drug Metabolism and Disposition October 1995, 23 (10) 1022-1027;

  5. Schaefer, W H

    1. Renal catabolism of recombinant human soluble CD4 after intravenous administration to male Sprague-Dawley rats.
      T W Hepburn, C B Davis, J J Urbanski, B R Smith, W H Schaefer, M A Carbonaro and P J Bugelski
      Drug Metabolism and Disposition October 1995, 23 (10) 1044-1050;

  6. Schiller, C D

    1. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
      B Valles, C D Schiller, P Coassolo, G De Sousa, R Wyss, D Jaeck, A Viger-Chougnet and R Rahmani
      Drug Metabolism and Disposition October 1995, 23 (10) 1051-1057;

  7. Schreier, K M

    1. Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.
      R J Bergeron, W R Weimar, G Luchetta, R R Streiff, J Wiegand, J Perrin, K M Schreier, C Porter, G W Yao and H Dimova
      Drug Metabolism and Disposition October 1995, 23 (10) 1117-1125;

  8. Shet, M S

    1. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.
      J M Machinist, M D Mayer, M S Shet, J L Ferrero and A D Rodrigues
      Drug Metabolism and Disposition October 1995, 23 (10) 1163-1174;

  9. Skinner, T L

    1. Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators.
      R A Yokel, A M Fredenburg, K A Meurer and T L Skinner
      Drug Metabolism and Disposition October 1995, 23 (10) 1178-1180;

  10. Sladek, N E

    1. Human breast adenocarcinoma MCF-7/0 cells electroporated with cytosolic class 3 aldehyde dehydrogenases obtained from tumor cells and a normal tissue exhibit differential sensitivity to mafosfamide.
      L Sreerama and N E Sladek
      Drug Metabolism and Disposition October 1995, 23 (10) 1080-1084;

  11. Smith, B R

    1. Renal catabolism of recombinant human soluble CD4 after intravenous administration to male Sprague-Dawley rats.
      T W Hepburn, C B Davis, J J Urbanski, B R Smith, W H Schaefer, M A Carbonaro and P J Bugelski
      Drug Metabolism and Disposition October 1995, 23 (10) 1044-1050;

  12. Sreerama, L

    1. Human breast adenocarcinoma MCF-7/0 cells electroporated with cytosolic class 3 aldehyde dehydrogenases obtained from tumor cells and a normal tissue exhibit differential sensitivity to mafosfamide.
      L Sreerama and N E Sladek
      Drug Metabolism and Disposition October 1995, 23 (10) 1080-1084;

  13. Streiff, R R

    1. Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.
      R J Bergeron, W R Weimar, G Luchetta, R R Streiff, J Wiegand, J Perrin, K M Schreier, C Porter, G W Yao and H Dimova
      Drug Metabolism and Disposition October 1995, 23 (10) 1117-1125;

T

  1. Trimble, L A

    1. Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile.
      D A Nicoll-Griffith, N Gupta, S P Twa, H Williams, L A Trimble and J A Yergey
      Drug Metabolism and Disposition October 1995, 23 (10) 1085-1093;

  2. Twa, S P

    1. Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile.
      D A Nicoll-Griffith, N Gupta, S P Twa, H Williams, L A Trimble and J A Yergey
      Drug Metabolism and Disposition October 1995, 23 (10) 1085-1093;

U

  1. Urbanski, J J

    1. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.
      C B Davis, T W Hepburn, J J Urbanski, D C Kwok, T K Hart, D J Herzyk, S G Demuth, M Leland and G R Rhodes
      Drug Metabolism and Disposition October 1995, 23 (10) 1028-1036;
    2. Renal catabolism of recombinant human soluble CD4 after intravenous administration to male Sprague-Dawley rats.
      T W Hepburn, C B Davis, J J Urbanski, B R Smith, W H Schaefer, M A Carbonaro and P J Bugelski
      Drug Metabolism and Disposition October 1995, 23 (10) 1044-1050;

V

  1. Valles, B

    1. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
      B Valles, C D Schiller, P Coassolo, G De Sousa, R Wyss, D Jaeck, A Viger-Chougnet and R Rahmani
      Drug Metabolism and Disposition October 1995, 23 (10) 1051-1057;

  2. Veltman, J C

    1. Minimal effects of two aldose reductase inhibitors, AL-1576 and AL-4114, after subacute topical-ocular dosing on xenobiotic biotransformation in rabbits.
      S G Sastry, R A Sanders, J C Veltman and J B Watkins
      Drug Metabolism and Disposition October 1995, 23 (10) 1094-1098;

  3. Vickers, S

    1. Use of gender and oxygenation as synonyms for sex and oxidation.
      S Vickers
      Drug Metabolism and Disposition October 1995, 23 (10) 1007;

  4. Viger-Chougnet, A

    1. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
      B Valles, C D Schiller, P Coassolo, G De Sousa, R Wyss, D Jaeck, A Viger-Chougnet and R Rahmani
      Drug Metabolism and Disposition October 1995, 23 (10) 1051-1057;

  5. Vyas, K P

    1. Disposition of DMP 811 (L-708,404), a potent angiotensin II receptor antagonist, in the rat, monkey, and chimpanzee.
      K E Zhang and K P Vyas
      Drug Metabolism and Disposition October 1995, 23 (10) 1104-1109;

W

  1. Watkins, J B

    1. Minimal effects of two aldose reductase inhibitors, AL-1576 and AL-4114, after subacute topical-ocular dosing on xenobiotic biotransformation in rabbits.
      S G Sastry, R A Sanders, J C Veltman and J B Watkins
      Drug Metabolism and Disposition October 1995, 23 (10) 1094-1098;

  2. Weimar, W R

    1. Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.
      R J Bergeron, W R Weimar, G Luchetta, R R Streiff, J Wiegand, J Perrin, K M Schreier, C Porter, G W Yao and H Dimova
      Drug Metabolism and Disposition October 1995, 23 (10) 1117-1125;

  3. Wiegand, J

    1. Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.
      R J Bergeron, W R Weimar, G Luchetta, R R Streiff, J Wiegand, J Perrin, K M Schreier, C Porter, G W Yao and H Dimova
      Drug Metabolism and Disposition October 1995, 23 (10) 1117-1125;

  4. Williams, H

    1. Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile.
      D A Nicoll-Griffith, N Gupta, S P Twa, H Williams, L A Trimble and J A Yergey
      Drug Metabolism and Disposition October 1995, 23 (10) 1085-1093;

  5. Wrighton, S A

    1. Human liver lauric acid hydroxylase activities.
      P J Castle, J L Merdink, J R Okita, S A Wrighton and R T Okita
      Drug Metabolism and Disposition October 1995, 23 (10) 1037-1043;

  6. Wyss, R

    1. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
      B Valles, C D Schiller, P Coassolo, G De Sousa, R Wyss, D Jaeck, A Viger-Chougnet and R Rahmani
      Drug Metabolism and Disposition October 1995, 23 (10) 1051-1057;

Y

  1. Yao, G W

    1. Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.
      R J Bergeron, W R Weimar, G Luchetta, R R Streiff, J Wiegand, J Perrin, K M Schreier, C Porter, G W Yao and H Dimova
      Drug Metabolism and Disposition October 1995, 23 (10) 1117-1125;

  2. Yergey, J A

    1. Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile.
      D A Nicoll-Griffith, N Gupta, S P Twa, H Williams, L A Trimble and J A Yergey
      Drug Metabolism and Disposition October 1995, 23 (10) 1085-1093;

  3. Yokel, R A

    1. Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators.
      R A Yokel, A M Fredenburg, K A Meurer and T L Skinner
      Drug Metabolism and Disposition October 1995, 23 (10) 1178-1180;

Z

  1. Zhang, K E

    1. Disposition of DMP 811 (L-708,404), a potent angiotensin II receptor antagonist, in the rat, monkey, and chimpanzee.
      K E Zhang and K P Vyas
      Drug Metabolism and Disposition October 1995, 23 (10) 1104-1109;
Back to top

In this issue